Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5

S. Das, N. Maulik, D. K. Das, P. J. Kadowitz, Trinity Bivalacqua

Research output: Contribution to journalArticle

Abstract

The effects of sildenafil (Viagra®), a specific inhibitor of phosphodiesterase 5, on ischemic myocardium was examined using an isolated rat heart model. Rats were pretreated with sildenafil at doses ranging from 0.001 mg to 0.5 mg/kg body weight. After 60 min, isolated hearts were subjected to ischemia for 30 min followed by 2 h of reperfusion. The results demonstrated that at 0.05 mg/kg (and to some extent at 0.01 mg/kg), sildenafil provided significant cardioprotection as evidenced by improved ventricular recovery, a reduced incidence of ventricular fibrillation and decreased myocardial infarction. At higher doses, it caused a significant increase in the incidence of ventricular fibrillation while at very low doses it had no effect on cardiac function. As expected, sildenafil increased cyclic 3′,5′-monophosphate (cGMP) content in the heart. The results demonstrate for the first time that within a narrow dose range, sildenafil can protect the heart from ischemia/reperfusion injury, probably through a cGMP-signaling pathway.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalDrugs under Experimental and Clinical Research
Volume28
Issue number6
StatePublished - 2002
Externally publishedYes

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Ventricular Fibrillation
Phosphodiesterase 5 Inhibitors
Incidence
Reperfusion Injury
Reperfusion
Sildenafil Citrate
Myocardium
Ischemia
Myocardial Infarction
Body Weight

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology
  • Drug Discovery

Cite this

Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5. / Das, S.; Maulik, N.; Das, D. K.; Kadowitz, P. J.; Bivalacqua, Trinity.

In: Drugs under Experimental and Clinical Research, Vol. 28, No. 6, 2002, p. 213-219.

Research output: Contribution to journalArticle

@article{db94c1ba65c24bd3a2401a234fe4b88d,
title = "Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5",
abstract = "The effects of sildenafil (Viagra{\circledR}), a specific inhibitor of phosphodiesterase 5, on ischemic myocardium was examined using an isolated rat heart model. Rats were pretreated with sildenafil at doses ranging from 0.001 mg to 0.5 mg/kg body weight. After 60 min, isolated hearts were subjected to ischemia for 30 min followed by 2 h of reperfusion. The results demonstrated that at 0.05 mg/kg (and to some extent at 0.01 mg/kg), sildenafil provided significant cardioprotection as evidenced by improved ventricular recovery, a reduced incidence of ventricular fibrillation and decreased myocardial infarction. At higher doses, it caused a significant increase in the incidence of ventricular fibrillation while at very low doses it had no effect on cardiac function. As expected, sildenafil increased cyclic 3′,5′-monophosphate (cGMP) content in the heart. The results demonstrate for the first time that within a narrow dose range, sildenafil can protect the heart from ischemia/reperfusion injury, probably through a cGMP-signaling pathway.",
author = "S. Das and N. Maulik and Das, {D. K.} and Kadowitz, {P. J.} and Trinity Bivalacqua",
year = "2002",
language = "English (US)",
volume = "28",
pages = "213--219",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "6",

}

TY - JOUR

T1 - Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′-monophosphate-specific phosphodiesterase 5

AU - Das, S.

AU - Maulik, N.

AU - Das, D. K.

AU - Kadowitz, P. J.

AU - Bivalacqua, Trinity

PY - 2002

Y1 - 2002

N2 - The effects of sildenafil (Viagra®), a specific inhibitor of phosphodiesterase 5, on ischemic myocardium was examined using an isolated rat heart model. Rats were pretreated with sildenafil at doses ranging from 0.001 mg to 0.5 mg/kg body weight. After 60 min, isolated hearts were subjected to ischemia for 30 min followed by 2 h of reperfusion. The results demonstrated that at 0.05 mg/kg (and to some extent at 0.01 mg/kg), sildenafil provided significant cardioprotection as evidenced by improved ventricular recovery, a reduced incidence of ventricular fibrillation and decreased myocardial infarction. At higher doses, it caused a significant increase in the incidence of ventricular fibrillation while at very low doses it had no effect on cardiac function. As expected, sildenafil increased cyclic 3′,5′-monophosphate (cGMP) content in the heart. The results demonstrate for the first time that within a narrow dose range, sildenafil can protect the heart from ischemia/reperfusion injury, probably through a cGMP-signaling pathway.

AB - The effects of sildenafil (Viagra®), a specific inhibitor of phosphodiesterase 5, on ischemic myocardium was examined using an isolated rat heart model. Rats were pretreated with sildenafil at doses ranging from 0.001 mg to 0.5 mg/kg body weight. After 60 min, isolated hearts were subjected to ischemia for 30 min followed by 2 h of reperfusion. The results demonstrated that at 0.05 mg/kg (and to some extent at 0.01 mg/kg), sildenafil provided significant cardioprotection as evidenced by improved ventricular recovery, a reduced incidence of ventricular fibrillation and decreased myocardial infarction. At higher doses, it caused a significant increase in the incidence of ventricular fibrillation while at very low doses it had no effect on cardiac function. As expected, sildenafil increased cyclic 3′,5′-monophosphate (cGMP) content in the heart. The results demonstrate for the first time that within a narrow dose range, sildenafil can protect the heart from ischemia/reperfusion injury, probably through a cGMP-signaling pathway.

UR - http://www.scopus.com/inward/record.url?scp=0037904833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037904833&partnerID=8YFLogxK

M3 - Article

C2 - 12776574

AN - SCOPUS:0037904833

VL - 28

SP - 213

EP - 219

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 6

ER -